Trend Chart on Innovative Bioindustries - September 12th FEATURE STORY The landscape of early clinical gene therapies outside oncology BASIC SCIENCE Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL CLINICAL TRIALS/DATA ATL1102 for DMD commencement of European regulatory interactions UniQure stays a step ahead in…..

$50 million in first close of new advanced therapies fund, 4BIO Ventures II 4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been committed from family offices…..

FEATURE STORY Pfizer adds 500MUS$ to gene therapy manufacturing plant GENE THERAPY AAV-ie enables safe and efficient gene transfer to inner ear cells. Recent advances in the targeting of systemically administered non-viral gene delivery systems DISRUPTIVE TECHNOLOGIES Efficient electroporation of neuronal cells using synthetic oligonucleotides Potential applications of nanoparticles for…..

Pfizer invests $500 million to advance state-of-the-art gene therapy facility Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s…..

AskBio Strengthens its Gene Therapy Technology Portfolio Asklepios Biopharmaceutical (AskBio), a US clinical-stage gene therapy platform company dedicated to rare genetic disorders, is currently expanding its technological capabilities. This AAV gene therapy company has now acquired Synpromics, a UK-based leader in gene  control synthetic promoter technology, bioinformatics and intelligent data-driven design…..

New CDMO acquisition for Keensight Capital Keensight Capital, a leading Paris-based private equity managers dedicated to pan-European Growth Buyout investments, has just acquired Infarco’s majority stake in 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics. Founded in 2006 and based near Pamplona, Spain,…..

 New collaboration to "silence" the complement cascade Mallinckrodt and Silence Therapeutics will collaborate to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins…..

Debiopharm and BIOASTER join forces against infectious diseases The Swiss biopharmaceutical company Debiopharm and BIOASTER, the French Technology Research Institute in infectiology have officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. This relationship will harness BIOASTER’s scientific and technical expertise, including technology platforms,…..